Nutritional (18%). Infections (9%) and hypersplenism (6%) etc accounted for the rest. All patients with megaloblastic anemia survived despite no transfusions. But patients with very severe Aplastic Anemia and hematological malignancies had worse outcomes despite ATG courses ; multiple transfusions and induction chemotherapy respectively.Patient with Kala Azar, chronic Malaria infections and hypersplenism survived after appropriate treatment.Also hospital stay was prolonged for leukemias and Aplastic Anemia. Conclusion: The etiology of pancytopenia varies widely ranging from transient marrow viral suppression, drugs etc to marrow infiltration by life-threatening malignancy.The severity of pancytopenia and the underlying pathology determine the management and prognosis of the patients .Hence such studies will help in planning the diagnostic and therapeutic approach in patients with pancytopenia and curtailing delays to reduce multiple transfusions, pre-treatment infections and overall morbidity and mortality associated with entity of Pancytopenia. Introduction: The Last three decades have witnessed profound changes in the management of patients with thalassemia major. Regular and periodic blood transfusion being the main stay of treatment results in iron overload thus necessitating need for iron chelation. At present three iron chelators namely, Desferrioxamine, Defriprone and defirasirox are in use alone or in combinations. Since the iron chelators are required to be given for the lifetime they also cause adverse events which are range from trivial to life threatening. Aims: To identify and manage adverse drug events due to iron chelating drugs experienced by thalassemic patients. Material and methods: This is an observational study done during 1st January to 30 th June 2016 in Thalassemia Day Care Centre of SMGS hospital, Govt. Medical College Jammu. All the adverse events were recorded on a pretested proforma and were validated on Naranjo causality assessment scale. Results: Of the 280 patients with the age ranging from 6 months to 53 years registered with Thalassemia Day Care Centre SMGS hospital Govt. Medical College Jammu only 180 attended regular fortnightly follow up clinics. Out of these 180 patients 168 are on Iron chelation drugs (129 on Defriprone, 24 on Defirasirox, 8 on Defriprone + Desferrioxamine, 4 on Desferrioxamine and 3 on Defriprone + Desferrixamin) Out of 32 events observed during the course of study 21 (65.62%) were due to Defriprone, 8 (25%) due to Deferasirox and 3 (9.38%) due to Desfferioxamine. Out of 21 events due to Defriprone 12 (57.14%) were gastrointestinal symptoms, 5 (23.8%) arthropathy, 2 (9.5%) Neutropenia and 2 (9.5%) thrombocytopenia. All 8 (100%) events due to Deferasirox were gastrointestinal symptoms. 2 (66.66%) events with desferrioxamine were local reactions and 1 (33.33%) was encephalitis. On Naranjo Casuality scale 5/32 was definite while as 24 /32 was probable and 3/32 were possible. While 9 were mild reactions, 4 were severe reactions and 19 were moderate reactions. Conclusion: Majority of adverse events were observed with Defriprone followed by Deferasirox. Although least adverse events were observed with desferrioxamine, but adverse events with deferasirox were least severe. Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33 S20
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